

Medical benefit oncology drugs that will require prior authorization through OncoHealth starting Jan. 1

As we announced in recent issues of *The Record* and *BCN Provider News*, OncoHealth[®] will manage prior authorizations for medical benefit oncology drugs through the Oncology Value Management program for dates of service on or after Jan. 1, 2025.

Most of the medical benefit oncology drugs that currently have requirements through Carelon Medical Benefits Management will continue to have requirements through OncoHealth. However, there are a few changes for dates of service on or after Jan. 1:

Drug	Change
Tevimbra [®] (tislelizumab-jsgr), HCPCS code J9329	For Blue Cross and BCN commercial members: We're adding both prior authorization and site-of-care requirements. Submit requests to OncoHealth.
	For Medicare Plus Blue and BCN Advantage members: We're adding a prior authorization requirement. Submit requests to OncoHealth.
Reblozyl [®] (luspatercept-aamt), HCPCS code J0896	For Blue Cross and BCN commercial members: Prior authorization and site-of-care requirements will be managed by OncoHealth. Submit requests to OncoHealth — not through the NovoLogix [®] online tool.
	For Medicare Plus Blue and BCN Advantage members: Prior authorization will be managed by OncoHealth. Submit requests to OncoHealth — not through NovoLogix [®] .
	For commercial and Medicare Advantage members: The medical policy for Reblozyl will be updated on Jan. 1, 2025. In keeping with the updated policy, approved authorizations will be valid for at least 60 days and up to six months. You can see the full list of requirements in the updated medical policy, which will be available no later than Jan. 1. To view the policy, go to the Medical Policy Router Search page, enter the name of the drug in the <i>Policy/Topic Keyword</i> field and press <i>Enter</i> .

We're also making some changes to our preferred drug designations. For details, see our provider alert [Changes to preferred drug designations under the medical benefit for most members, starting Jan. 1.](#)

Watch for provider alerts and articles in our provider newsletters, *The Record* and *BCN Provider News*, about when and how you can start submitting prior authorization requests to OncoHealth for dates of service on or after Jan. 1, 2025.



Nonprofit corporations and independent licensees
of the Blue Cross and Blue Shield Association

Provider alert

Blue Cross commercial, Medicare Plus BlueSM,
BCN commercial and BCN AdvantageSM

Category: Authorizations/referrals, Pharmacy

Date posted: Sept. 24, 2024

In addition, we'll provide complete lists of medical benefit oncology drugs that will have requirements under the Oncology Value Management program through OncoHealth before Jan. 1, 2025.

To view lists of drugs that currently require prior authorization through Carelon, see the following documents:

- [Oncology Value Management program prior authorization list for Blue Cross and BCN commercial members: Medications that require authorization by Carelon](#)
- [Medical Drug and Step Therapy Prior Authorization List for Medicare Plus Blue and BCN Advantage members](#)

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.

Carelon Medical Benefits Management is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to manage prior authorizations for select services.

OncoHealth is an independent company supporting Blue Cross Blue Shield of Michigan and Blue Care Network by providing cancer support services.